Main Article Content
Candidiasis is the most prevalence opportunistic fungal infection of humans, and invasive Candida infections remain an important cause of morbidity and mortality, especially in hospitalized and immunocompomised patients. Recent investigation revealed that simultaneous combination of caspofungin and fluconazole appeared to affect the quantity and cell architecture of C. albicans and C. glabrata mixed biofilm in vitro. The objective of this study was to further investigate the effect of caspofungin (CAS) sequentially combined with fluconazole (FLU) on the vitality and quantity of mixed C. albicans and C. glabrata biofilm. Viability of biofilms was evaluated by 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino)carbonyl)]-2H-tetrazolium hydroxide (XTT) assay and biomass of biofilm was assessed by crystal violet assay. The inhibitory effects of sequential CAS-FLU combinations on the biomass of biofilm were significantly declined when mixed biofilms were pretreated with FLU for a longer period of time over 3 h (p < 0.001), however, the vitality of FLU-pre exposed mixed biofilms in response to CAS-FLU combination treatment were not different. The biomass reduction effect of CAS-FLU combinations was dependent on the sequence of initial of drugs combination and the pre-exposure time. Conclusion, sequential CAS-FLU combinations treatment had an impact on the biomass but not viability of mixed C. albicans and C. glabrata biofilm.
Arana, D., Alonso-Monge, R., Du, C., Calderone, R. and Pla, J., 2007, Differential susceptibility of mitogen-activated protein kinase pathway mutants to oxidative-mediated killing by phagocytes in the fungal pathogen Candida albicans, Cell Microbiol. 9: 1647-1659.
Bachmann, S.P., VandeWalle, K., Ramage, G., Patterson, T.F., Wickes, B.L., Graybill, J.R. and Lo´pez-Ribot, J.L., 2002, In vitro activity of caspofungin against Candida albicans biofilms, Antimicrob. Agents. Chemother. 46 : 3591-3596.
Barchiesi, F., Spreghini, E., Baldassarri, I., Marigliano, A., Arzeni, D., Giannini, D. and Scalise, G., 2004, Sequential therapy with caspofungin and fluconazole for Candida albicans infection, Antimicrob. Agents. Chemother. 48: 4056-4058.
Chandra, J., Kuhn, D., Mukherjee, P., Hoyer, L., McCormick, T. and Ghannoum, M., 2001a, Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance, J. Bacteriol. 183: 5385-5394.
Chandra, J., Mukherjee, P.K., Leidich, S.D., Faddoul, F.F., Hoyer, L.L., Douglas, L.J. and Ghannoum, M.A., 2001b, Antifungal resistance of candidal biofilms formed on denture acrylic in vitro, J . Dent. Res. 80: 903-908.
Coco, B., Bagg, J., Cross, L., Jose, A., Cross, J. and Ramage, G., 2008, Mixed Candida albicans and Candida glabrata populations associated with the pathogenesis of denture stomatitis, Oral Microbiol. Immunol. 23: 377-383.
Flevari, A., Theodorakopoulou, M., Velegraki, A., Armaganidis, A. and Dimopoulos, G., 2013, Treatment of invasive candidiasis in the elderly: a review, Clin. Intervent. Aging. 8: 1199-1208.
Hawser, S., Baillie, G. and Douglas, L., 1998, Production of extracellular matrix by Candida albicans biofilms, J. Med. Microbiol. 47: 253-256.
Horn, D.L., Neofytos, D., Anaissie, E.J., Fishman, J.A., Steinbach, W.J., Olyaei, A.J., Marr, K.A., Pfaller, M.A., Chang, C. and Webster, K.M., 2009, Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry, Clin. Infect. Dis. 48: 1695-1703.
Jogalekar, A.P., Ashrit, P., Vijayalakshmi, V., Prathima, P.T., Tejaswini, R.P., Chandana, G.K. and Sadanandan, B., 2014, Comparative study on Candida biofilm quantification methods, Inter. Rev. Appl. Biotechnol. Biochem. 2: 133-138.
Klipp, E., Nordlander, B., Kruger, R., Gennemark, P. and Hohmann, S., 2005, Integrative model of the response of yeast to osmotic shock, Nat. Biotechnol. 23: 975-982.
Kontoyiannis, D.P. and Lewis, R.E., 2004, Toward more effective antifungal therapy: the prospects of combination therapy, Br. J. Heamatol. 126: 165-175.
Kuhn, D., Chandra, J., Mukherjee, P. and Ghannoum, M., 2002, Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces, Infect. Immun. 70: 878-888.
Kuhn, C. and Klipp, E., 2012, Zooming in on yeast osmoadaptation. Adv. Experiment, Med. Biol. 736: 293-310.
Mavor, A., Thewes, S. and Hube, B., 2005, Systemic fungal infections caused by Candida species: Epidemiology, infection process and virulence attributes, Curr. Drug Targets. 6: 863-874.
Muadcheingka, T. and Tantivitayakul, P., 2015, Distribution of Candida albicans and non-albicans Candida species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities, Arch. Oral Biol. 60: 894-901.
Mukherjee, P.K. and Chandra, J., 2004, Candida biofilm resistance, Drug Resist. Updat. 7: 301-309.
Nailis, H., Vandenbosch, D., Deforce, D., Nelis, H. and Coenye, T., 2010, Transcriptional response to fluconazole and amphotericin B in Candida albicans biofilms, Res. Microbiol. 16: 284-292.
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M. and Andes, D., 2007, Putative role of beta-1,3 glucans in Candida albicans biofilm resistance, Antimicrob. Agents. Chemothe. 51: 510-520.
Pathak, A.K., Sharma, S. and Shrivastva. P., 2012, Multi-species biofilm of Candida albicans and non-Candida albicans Candida species on acrylic substrate, J. Appl. Oral Sci. 20: 70-75.
Patterson, M., McKenzie, C., Smith, D., da Silva Dantas, A., Sherston, S., Veal, E.A., Morgan, B.A., MacCallum, D.M., Erwig, L.P. and and Quinn, J., 2013, Ybp1 and Gpx3 signaling in Candida albicans govern hydrogen peroxidase-induced oxidation of the Cap1 transcription factor and macrophage escape, Antioxid. Redox. Signal. 19: 2244-2260.
Pemmaraju, S., Padmapriya, K., Pruthi, P., Prasad, R. and Pruthi, V., 2016, Impact of oxidative and osmotic stresses on Candida albicans biofilm formation, Biofouling 32: 897-909.
Pesee, S., Angkananuwat, C., Tancharoensukjit, S., Muanmai, S., Sirivan, P., Bubphawas, M. and Tanarerkchai N., 2016, In vitro activity of caspofungin combined with fluconazole on mixed Candida albicans and Candida glabrata biofilm, Med. Mycol. 54: 384-393.
Pfaller, M. and Riley, J., 1992, Effects of fluconazole on the sterol and carbohydrate composition of four species of Candida, Eur. J. Clin. Microbiol. Infect. Dis. 11: 152-156.
Ramage, G., Wickes, B.L. and Lopez-Ribot, J.L., 2001, Biofilms of Candida albicans and their associated resistance to antifungal agents, Am. Clin. Lab. 20: 42-44.
Redding, S.W., Dahiya, M.C., Kirkpatrick, W.R., Coco, B.J., Patterson, T.F., Fothergill, A.W., Rinaldi, M.G. and Thomas, C.R.Jr., 2004, Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receivig radiation for head and neck cancer, Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 97: 47-52.
Rodrigues, C.F., Rodrigues, M.E. and Henriques, M. 2018, Susceptibility of Candida glabrata biofilms to echinocandins: Alterations in the matrix composition, Biofouling 34: 569-578.
Sarkar, S., Uppuluri, P., Pierce, C.G. and Lopez-Ribot, J.L., 2014, In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms, Antimicrob. Agents. Chemother. 58: 1183-1186.
Silva, S., Henriques, M., Hayes, A., Oliveira, R., Azeredo, J. and Williams, D.W., 2011, Candida glabrata and Candida albicans co-infection of an in vitro oral epithelium, J. Oral Pathol. Med. 40: 421–427.
Taff, H.T., Mitchell, K.F., Edward, J.A. and Andres, D.R., 2013, Mechanisms of Candida biofilm drug resistance, Future Microbiol. 8: 1325-1337.
Walker, L., Gow, N. and Munro, C., 2013, Elevated chitin content reduces the susceptibility of Candida species to caspofungin, Antimicrob. Agents. Chemother. 57: 146-154.
Wisplinghoff, H., Bischoff, T., Tallent, S. Seifert, H., Wenzel, R.P. and Edmond, M.B., 2004, Nosocomial blood stream infections in US hospitals: Analysis of 24,179 cases from a propective nationwide surveillance study, Clin. Infect. Dis. 39: 309-317.